

ACCEPTANCE REVIEW MEMO (ARM)

Licensee: St. Luke's Regional Medical Center **License No.:** 11-27312-01
Docket No.: 030-32196 **Mail Control No.:** 471224
Type of Action: Notify **Date of Requested Action:** 12-14-06
Reviewer Assigned: **ARM reviewer(s):** *Jarvis + Cook*

Response	Deficiencies Noted During Acceptance Review
	<input type="checkbox"/> Open ended possession limits. Limit possession. Submit inventory. <input type="checkbox"/> Submit copies of most recent leak test results. <input type="checkbox"/> Add - delete IC license condition. Add IC paragraph in cover letter. <input type="checkbox"/> Split license from cover letter. Add SUNSI marking to license. <input type="checkbox"/> Ask the licensee if they have any type-amount of EPAct Material.

RTC

Reviewer's Initials: _____ **Date:** _____

Yes No Unrestricted release Group 2 or >: Transfer memo to FCDB within 10 days.
 Yes No Decommissioning notification should be completed within 30 days.
 Yes No Termination request < 90 days from date of expiration
 Yes No Expedite (medical emergency, no RSO, location of use/storage not on license, RAM in possession not on license, other)
 Yes No TAR needed to complete action.

Branch Chief's and/or Sr. HP's Initials: _____ **Date:** _____

SUNSI Screening according to RIS 2005-31

Yes No **Non-Publicly Available, Sensitive** if any item below is checked

General guidance:

- _____ RAM = or > than Category 3 (Table 1, RIS 2005-31), use Unity Rule
- _____ Exact location of RAM (whether = or > than Category 3 or not)
- _____ Design of structure and/or equipment (site specific)
- _____ Information on nearby facilities
- _____ Detailed design drawings and/or performance information
- _____ Emergency planning and/or fire protection systems

Specific guidance for medical, industrial and academic (above Category 3):

- _____ RAM quantities and inventory
- _____ Manufacturer's name and model number of sealed sources & devices
- _____ Site drawings with exact location of RAM, description of facility
- _____ RAM security program information (locks, alarms, etc.)
- _____ Emergency Plan specifics (routes to/from RAM, response to security events)
- _____ Vulnerability/security assessment/accident-safety analysis/risk assess
- _____ Mailing lists related to security response

Branch Chief's and/or Sr. HP's Initials: *RTC* **Date:** *4/1/07*

Pre-Licensing Screening

Applicant Information:

Control No. 471224

Name: St. Lukes Regional Medical Center	Type of Request: Amend Program Code(s):
Location: ID	License No.: 11-27312-01 Docket No.: 030-32196

STEP 1—Radioactive Materials and Quantities Requested:

Instructions for Step 1: Complete Step 1 for all applications. If all your responses in Step 1 are "No" then do not complete Step 2 (Screening Criteria). Sign and date the completed step-sheet and add it as the sensitive and non-publicly available OAR in ADAMS. If a "yes" response is indicated for any item in Step 1, also complete Step 2. If the type of use is subject to a Security Order or the requirements for increased controls, complete Step 3 (Item A or Item B) without delay.		Yes or No
A.	The request is from a new applicant.	N
B.	NUREG-1556, Volume 20, Section 4.9 indicates a licensing site visit is needed for the requested type of use, e.g., (1) Type A broad scope license, (2) panoramic irradiator containing > 10000 curies, (3) manufacturers or distributors using unsealed radioactive material or significant quantities of sealed material, (4) radioactive waste brokers, (5) radioactive waste incinerators, (6) commercial nuclear laundries, and (7) any other application that in the judgement of the reviewer and cognizant supervisor involves complex technical issues, complex safety questions, or unprecedented issues that warrant a site visit.	N
C.	The applicant requested certain radionuclides and quantities that equal or exceed the Risk Significant Quantity (TBq) values in the table, below, that have been "highlighted" by the reviewer	N

Table of Risk Significant Quantities

(Category 2 Quantities, IAEA Safety Guide No. RS-G-1.9, Categorization of Radioactive Sources, August 2005)

Radionuclide	Risk Significant Quantity (TBq ¹)	Risk Significant Quantity (Ci ¹)	Radionuclide	Risk Significant Quantity (TBq ¹)	Risk Significant Quantity (Ci ¹)
Am-241	0.6	16	Pm-147	400	11,000
Am-241/Be	0.6	16	Pu-238	0.6	16
Cf-252	0.2	5.4	Pu-239/Be	0.6	16
Cm-244	0.5	14	Ra-226 ²	0.4	11
Co-60	0.3	8.1	Se-75	2	54
Cs-137	1	27	Sr-90 (Y-90)	10	270
Gd-153	10	270	Tm-170	200	5,400
Ir-192	0.8	22	Yb-169	3	81

¹ The primary values are TBq. The curie (Ci) values are for informational purposes only.
² The Atomic Energy Act, as amended by the Energy Policy Act of 2005, authorizes NRC to regulate Ra-226 and NRC is in the process of amending its regulations for discrete sources of Ra-226.

Calculations of the Total Activity or the Unity Rule are attached to document whether or not the screening criteria in Step 2 were also completed to evaluate the application. NOTE—If an amendment of an existing license is being requested, the calculations will include the previously authorized quantities for the radionuclide(s).	Yes, No, or Not Applicable (NA)
Total Activity—multiple activities are requested for a single radionuclide and the sum of the activities equals or exceeds the quantity of concern for the radionuclide	—
Unity Rule—multiple radionuclides are requested and the sum of the ratios equals or exceeds unity, e.g., [(total activity for radionuclide A) + (risk significant quantity for radionuclide A)] + [(total activity for radionuclide B) + (risk significant quantity for radionuclide B)] ≥ 1.0.	—

Signature and Date for Step 1:

RITZ 1/11/07

License Reviewer and Date



520 S. Eagle
Meridian, ID 83642
(208) 706-5281
(208) 706-5046 - Fax

MS
St. Luke's
030-32196
✓

Date: 12/14/06

From: Jefferson Fairbanks

To: Jacqueline Cook

Phone: 208 706 1412

Fax # 817-860-8263

Re: License Amendment Request

Pages (Including cover sheet) 10

Urgent For Review Please Comment Please Reply

Hi Jackie,

Please find the attached request.

Jeff

This message is intended for the use of the person or entity to which it is addressed and may contain information that is confidential or privileged, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this information is strictly prohibited. If you have received this message by error, please notify us immediately and destroy the related message.



December 14, 2006

US Nuclear Regulatory Commission Region IV
Nuclear Materials Licensing Branch
611 Ryan Plaza Drive
Suite 400
Arlington, Texas 76011-8064

RE: Amendment of License #11-27312-01

Dear Sir or Madam:

This letter is notification to the Nuclear Regulatory Commission per 35.14 that Michael J. Citrone, M.D. will be an authorized user on our license for 10 CFR 35.100, 35.200, 35.300 and 35.500. He meets the criteria specified in 10 CFR 35.190(a), 35.290(a), 35.390(a) and 35.590(a). A copy of the radioactive materials license from the agreement state of Oregon is included in this request. I have also included additional documentation of his credentials.

Please amend our license to add his name as an authorized user.

For further information, please contact me at 208-381-3192 or 208-706-1412.

Sincerely,

Jefferson Fairbanks, PhD
Radiation Safety Officer

100 E. Idaho Street
Boise, ID 83712
(208) 381-2711
(800) 845-4624 • (208) 381-2974 (fax)

1118 NW 16th Street, Suite D
Fruitland, ID 83619
(208) 452-7677
(800) 473-9818 • (208) 452-8681 (fax)

520 S. Eagle Road
Meridian, ID 83642
(208) 706-6651
(800) 473-0331 • (208) 706-5344 (fax)

308 E. Hawaii Avenue
Nampa, ID 83686
(208) 467-6700
(800) 553-6415 • (208) 463-6001 (fax)

656 Addison Avenue W
Twin Falls, ID 83301
(208) 737-2441
(800) 947-4852 • (208) 737-2864 (fax)

Thomas M. Beck, MD
Medical Director

Luana Lamkin
Administrator

Theodore A. Walters, MD
Research Director MSTI/MSTMRI

Medical Hematology/Oncology
Thomas M. Beck, MD
Norman Zuckerman, MD
Paul G. Montgomery, MD
William H. Kresale, MD
Mary E. Geom, MD
Larry Fiorentino, MD
Theodore A. Walters, MD
Jonathan N. Swerdloff, MD
Jason Stinnett, MD
Brian E. Symington, MD
Lisa Y. Law, MD
Richard Miranda, MD
Kathleen Clifford, FNP
Cheryl Mills, FNP
Linda Erlanson, FNP
Dorene Boydston, FNP

Pediatric Hematology/Oncology
Eugenia Chang, MD
J. Martin Johnston, MD
Nicolas A. Camilo, MD
Marni Allen, FNP

Radiation Oncology
Charles E. Smith, MD
Ronald V. Dorn, III, MD
Sarah L. Bolender, MD
Stephen C. Smith, MD
Tonya L. Kuhn, MD
Colleen Lambert, FNP
Jerrini Helmick, FNP

Surgery
John A. Lung, MD

GYN Oncology
Jerry Perez, MD

Radiation Oncology
Medical Hematology/Oncology
Blood and Bone Marrow Transplantation
Clinical Research
Psychosocial Support
Wound, Ostomy, Continence Nursing
Surgery
Stereotactic Radiotherapy
High Dose Rate Brachytherapy
Inpatient Oncology Services
Pediatric Oncology/Hematology
Necropsy
Patient Guest Housing
Breast Cancer Detection Centers
Marrow Donor Center
Hemophilia
Integrative Medicine Program
Genetic Counseling
GYN Oncology
Mole Mapping



DEPARTMENT OF THE ARMY
HEADQUARTERS, TRIPLER ARMY MEDICAL CENTER
1 JARRETT WHITE ROAD
TRIPLER AMC, HAWAII 96858-5000



MCHK-DR

2 October 2006

TO: Credentials

FROM: Gregory Petermann, COL, Program Director, Tripler Army Medical Center, Honolulu, HI

SUBJECT: Nuclear Medicine certification of Dr Michael Citrone, M.D.

To Whom It May Concern:

1. Dr Michael Citrone trained at Tripler Army Medical Center Radiology residency program from July 1993 to June 1997. He is board certified in Diagnostic Radiology by the American Board of Radiology. He received classroom and laboratory training in basic radioisotope handling techniques applicable to the use of prepared radiopharmaceuticals, generators, and reagent kits, supervised work experience, and supervised clinical experience. He received over 200 hours of classroom and laboratory training including Radiation physics and instrumentation, Radiation protection, mathematics pertaining to the use and measurement of radioactivity, Radiopharmaceutical chemistry, Radiation biology.
2. Dr. Citrone received 500 hours of supervised work experience under the supervision of an authorized user. This included ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys, calibrating dose calibrators and diagnostic instruments and performing checks for proper operation of survey meters, calculating and safely preparing patient or human research subject dosages, using administrative controls to prevent the medical event of byproduct material, using procedures to contain spilled byproduct material safely and using proper decontamination procedures, eluting technetium-99m from generator systems, measuring and testing the eluate for molybdenum-99 and alumina contamination, and processing the eluate with reagent.
3. 500 hours of supervised clinical experience during residency training included supervision under an authorized user. This included examining patients or human research subjects and reviewing their case histories to determine their suitability for radioisotope diagnosis, limitations, or contraindications, selecting the suitable radiopharmaceuticals and calculating and measuring the dosages, administering dosages to patients or human research subjects and using syringe radiation shields, collaborating with the authorized user in the interpretation of radioisotope test results and patient or human research subject follow up.
4. Dr Citrone successfully completed 8-months of nuclear medicine rotations in our residency training program which is approved by the Accreditation Council for Graduate Medical Education. It included the classroom and laboratory training, work experience, and supervised clinical experience in all the topics listed above. Upon his graduation, he successfully passed his American Board of Radiology examination which included nuclear medicine image interpretation.
5. Based on this data, Dr Citrone was certified to interpret nuclear medicine studies at the time he completed his residency.

Gregory Petermann
COL, MC
Director, Radiology Residency Program
Tripler Army Medical Center
Honolulu, HI

Certificate of Achievement

Creative Educational Concepts Foundation certifies that

MICHAEL J. CITRONE, MD

PARTICIPATED IN THE FOLLOWING ACTIVITY:

PET & PET/CT PRECEPTORSHIP PROGRAM

SACRAMENTO, CA

DECEMBER 8-10, 2004

planned and implemented in accordance with the Essentials Areas and Policies of the Accreditation Council for Continuing Medical Education sponsorship of the Creative Educational Concepts Foundation (CEC Foundation). CEC Foundation is accredited by the ACCME to provide continuing physicians. CEC Foundation designates this educational activity for a maximum of 23.25 category 1 credits toward the AMA Physician's Recognition should claim only those credits that he/she actually spent in the activity.

23.25

(participant to complete) credit(s) for this activity.

NORTHERN CALIFORNIA
PET Imaging Center

Participant Signature

ni, ph
Participant Director
Education, Sponsor
Educational Concepts Foundation, Inc
616 Drake, Lexington KY 40503
7-1717, fax (859) 276-6118
www.cec

Joint Sponsor: The EduMed Corporation,
9360 Excelsior Avenue South, Suite 100,
Minneapolis, MN 55438
phone (952) 932-9922, fax (952) 932-9993
e-mail eddy@edumed.com www.edumed.com



Joint Sponsor
EduMed

Connecting the Medical World Through Education

471224

STATE OF OREGON
 OREGON STATE HEALTH DIVISION
 DEPARTMENT OF HUMAN SERVICES

Page 1 of 4 Pages
 License No. ORE-90373
 Amendment Number 32

RADIOACTIVE MATERIALS LICENSE

Pursuant to the Radiation Control Act and the Oregon Rules for the Control of Radiation, and in reliance on statements and representations heretofore made by the Licensee designated below, a license is hereby issued authorizing such licensee to transfer, receive, possess and use the radioactive material(s) designated below; and to use such radioactive materials for the purpose(s) and at the place(s) designated below. This license is subject to all applicable rules, regulations, and orders now or hereafter in effect of the State Health Division and to any and all conditions specified below.

In accordance with application dated May 16, 2005 and facsimile document dated June 6, 2005, Oregon Radioactive Materials License Number ORE-90373 is amended in its entirety to read as follows:

<p style="text-align: center;">Licensee</p> <p>Mercy Medical Center, Inc.</p> <p>1. Name</p> <p>2700 Stewart Parkway</p> <p>2. Address Roseburg, Oregon 97470</p>	<p>3. License Number ORE-90373</p> <hr/> <p>4. Expiration Date May 31, 2009</p> <hr/> <p>5. Reference Number Medical Diagnostic/Therapy QMP</p>
--	--

6. Radioactive materials (element and mass number)	7. Chemical and/or physical form	8. Maximum quantity licensee may possess at any one time
A. Any radioactive material identified in OAR 333-116-0300	A. Any radiopharmaceutical identified in OAR 333-116-0300	A. As needed.
B. Any radioactive material identified in OAR 333-116-0320	B. Any radiopharmaceutical identified in OAR 333-116-0320	B. As needed.
C. Any radioactive material identified in OAR 333-116-0360	C. Any radiopharmaceutical identified in OAR 333-116-0360	C. 18.5 GBq (500 millicuries).
D. Xenon-133	D. Gas	D. 7.4 GBq (200 millicuries).
E. Any radioactive material identified in OAR 333-116-0420	E. Any brachytherapy source identified in OAR 333-116-0420	E. 68.8 GBq (1,860 millicuries).
F. Gadolinium-153	F. Sealed source (Siemens Model NES8426)	F. Twenty eight sources not to exceed 0.74 GBq (20 millicuries) each.

9. Authorized use.

- A. Medical use as described in OAR 333-116-0300.
- B. Medical use as described in OAR 333-116-0320.
- C. Medical use as described in OAR 333-116-0360.
- D. Gas to be used for lung imaging and evaluation of pulmonary function.

STATE OF OREGON
DEPARTMENT OF HUMAN SERVICES
HEALTH SERVICES
RADIOACTIVE MATERIALS LICENSE

Page 2 of 4 Pages
License No. ORE-90373
Amendment Number 32

Continued from Page 1

9. Authorized use. (cont.)

- E. Medical use as described in OAR 333-116-0420.
- F. To be used in Siemens Model ECAM gamma camera system for non-linear attenuation correction systems.

CONDITIONS

- 10. 1. Licensed radioactive material shall be used only at the licensee's facilities located at 2700 Stewart Parkway, Roseburg, Oregon 97470.
- 2. Sentinel Node biopsies may also be performed at the Oregon Surgery Center, located on Mercy Medical Center campus.
- 11. This license is subject to and void without an annual validation certificate. Insofar as the licensee has submitted the proper fee prior to the expiration of a validation certificate, such existing validation certificate shall not expire until the issuance of a new validation certificate for the then current fiscal year.
- 12. A. The Radiation Safety Officer for the activities authorized by this license is Kenneth L. Linden, M.D.
- B. The Assistant Radiation Safety Officer for the activities authorized by this license is J.G. Warren, M.D.
- 13. A. Licensed radioactive material listed in Item 6 above is authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

<u>NAME</u>	<u>USE</u>
Robert Bennett, M.D.	Subitems A, B, D and F
Richard A. Osborn, M.D.	Subitems A, B, D and F
David G. Seibel, D.O.	Subitems A, B, D and F
Kenneth L. Linden, M.D.	Subitems A, B, D and F
Paul Guisler, M.D.	Subitems A, B, D and F
Diwaker Agarwal, M.D.	Subitems A, B, D and F
Michael J. Citrone, M.D.	Subitems A, B, D and F
Jerry G. Warren, M.D.	Subitems A, B, C, D, E and F
Sylvia Gosline, M.D.	Subitems C and E
Patrice McGowan, M.D.	Subitems C and E
R. Eugene Licnert, M.D.	Subitems C and E

Continued from Page 2

CONDITIONS (cont.)

STATE OF OREGON
 DEPARTMENT OF HUMAN SERVICES
 HEALTH SERVICES
RADIOACTIVE MATERIALS LICENSE

Page 3 of 4 Pages
 License No. ORE-90373
 Amendment Number 32

- (13.) B. Iodine-131 for treatment of hyperthyroidism as described in OAR 333-116-0360 may also be used by David G. Seibel, D.O., Kenneth L. Linden, M.D., or Paul Guisler, M.D.
- 14. A. Notwithstanding the requirement to prepare and use drugs in accordance with the package insert, if, in the judgment of the physician as authorized user, departures from the package insert, or use of unapproved drugs, is indicated, the physician may perform such procedures consistent with good professional medical practice as judged by the Oregon Board of Pharmacy, the Oregon Board of Medical Examiners, and/or the Oregon Radiation Advisory Board, as appropriate.
- B. Procedures shall be done by, or under the supervision of, persons whose training meets the requirements in OAR 333-116 and shall be in accordance with safe radiation safety procedures and ALARA in OAR 333-120. Radiopharmaceuticals shall not be used in humans until their pharmaceutical quality and assay have been established. Records documenting radioactive material used described in A. of this condition shall be kept by the licensee until inspection by the Agency.
- 15. Insofar as the licensee restricts the possession of radioactive material to quantities below the minimum limit specified in Appendix B of 10 CFR 30.35, the licensee is not required to provide financial assurance pursuant to OAR 333-102-0200(6).
- 16. The licensee shall comply with requirements in OAR 333-120-650 (records of internal dose) and OAR 333-102-0305(23) for materials stored for decay pursuant to OAR 333-116-0290.
- 17. Notwithstanding OAR 333-116-0320(4), Technetium-99m pentetate as an aerosol for lung function studies may be used, provided the conditions of OAR 333-116-0340 are met. A licensee shall use other radioactive aerosols or gases only if specific application is made to and approved by the Agency.
- 18. The licensee is authorized to receive, possess and use as reference and calibration sources:
 - A. Sealed sources of radioactive material containing cobalt-57 not to exceed 20 millicuries.
 - B. Sealed sources of radioactive material with a half-life longer than 100 days in individual amounts not to exceed 1 millicurie.
 - C. Technetium-99m in individual amounts not to exceed 50 millicuries.
- 19. Notwithstanding the requirements in OAR 333-120-0180 and pursuant to the requirements in 333-116-0260, the licensee is authorized to release a patient who has been administered therapeutic radiopharmaceuticals or permanent implants containing radioactive material if the total effective dose equivalent (TEDE) to any other individual is not likely to exceed 500 mrem. Upon release, the licensee shall:
 - (1) Provide the patient with written instructions to maintain doses to other individuals as low as reasonably achievable if the TEDE to any other individual is likely to exceed 5 millisieverts (0.5 rem);

STATE OF OREGON
DEPARTMENT OF HUMAN SERVICES
HEALTH SERVICES
RADIOACTIVE MATERIALS LICENSEPage 4 of 4 Pages
License No. ORE-90373
Amendment Number 32

Continued from Page 3

CONDITIONS (cont.)

- (19.) (2) Maintain, for three years after the date of release, a record of the basis for authorizing patient release if the TEDE is calculated:
- A. using the retained activity rather than the activity administered
 - B. using an occupancy factor less than 0.25 at 1 meter
 - C. using the biological or effective half-life, or
 - D. considering shielding by tissue
- (3) Maintain a record, for three years after the date of release, showing that instructions were provided to a breast-feeding woman if the radiation dose to the infant or child from continued breast-feeding could result in a TEDE exceeding 5 millisieverts (0.5 rem).
20. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations and procedures contained in the documents, including any enclosures listed below. The Oregon Rules for the Control of Radiation shall govern, unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the rules.
- A. Application dated May 16, 2005, signed by L. Ed Cox, Director, Imaging Services.
 - B. Facsimile document dated June 6, 2005, from Steven Lane, CNMT.

Date: August 17, 2005

FOR DHS HEALTH SERVICES

By Edwin L. Wright
Edwin L. Wright, Manager
Radioactive Materials Licensing Program

FROM :

FAX NO. : 8586948178

Aug. 17 2006 10:21AM P2

IDAHO STATE BOARD OF MEDICINE
P.O. Box 83720 - Boise, Idaho 83720-0058

This certifies that

MICHAEL JOSEPH CITRONE MD

Holds Idaho license as a

PHYSICIAN AND SURGEON

License No. M-9418
Expire Date: 08/30/2007

Nancy Kerr
Executive Director

*Duplicate copy of your
license is attached for
your convenience for
use with
credentialing/hospital
privilege actions.*

IDAHO STATE BOARD OF MEDICINE
P.O. Box 83720 - Boise, Idaho 83720-0058

This certifies that

MICHAEL JOSEPH CITRONE MD

Holds Idaho license as a

PHYSICIAN AND SURGEON

License No. M-9418
Expire Date: 08/30/2007

Nancy Kerr
Executive Director

MICHAEL JOSEPH CITRONE MD

10/21/2005

mcitrone01@cyber.com

The American Board of Radiology

Organized through the cooperation of the American College of Radiology, the American Roentgen Ray Society, the American Radium Society, the Radiological Society of North America, the Section on Radiology of the American Medical Association, the American Society for Therapeutic Radiology and Oncology, the Association of University Radiologists, and American Association of Physicians in Medicine

Hereby certifies that

Michael Joseph Citrone, M.D.

Has pursued an accepted course of graduate study and clinical work, has met certain standards and qualifications and has passed the examinations conducted under the authority of

The American Board of Radiology

On this eleventh day of June, 1997

Thereby demonstrating to the satisfaction of the Board that he is qualified to practice the specialty of

Diagnostic Radiology



James S. Anderson, MD President *Robert R. Henry, MD* Secretary-Treasurer *M. Paul Capp, M.D.* Executive Director

JAN 16 2007

DATE

This is to acknowledge the receipt of your letter/application dated 12-14-06, and to inform you that the initial processing, which includes an administrative review, has been performed.

There were no administrative omissions. Your application will be assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card:

The action you requested is normally processed within 90 days.

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 471224.
When calling to inquire about this action, please refer to this mail control number.
You may call me at 817-860-8103.

Sincerely,



Licensing Assistant

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)
INFORMATION FROM LTS

Program Code: 02230
Status Code: 0
Fee Category: 7C 3E EX 2B
Exp. Date: 20140930
Fee Comments: REF IDA-13-2
Decom Fin Assur Reqd: N

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee: ST. LUKES REGIONAL MEDICAL CENTER
Received Date: 20061214
Docket No: 3032196
Control No.: 471224
License No.: 11-27312-01
Action Type: Amendment

2. FEE ATTACHED

Amount: _____
Check No.: _____

3. COMMENTS

Signed *William J. ...*
Date 01-09-07

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /_/_)

1. Fee Category and Amount: _____

2. Correct Fee Paid. Application may be processed for:

Amendment _____
Renewal _____
License _____

3. OTHER _____

Signed _____
Date _____